NewsEvents

Your Yourlocation: Home > The status of tiotropium bromide(136310-93-5) in children with asthma remains to be further defined

Recent Phase III clinical studies published in the European Journal of Respiratory have explored the efficacy of tiotropium bromide(136310-93-5) in children with more severe asthma. The study was designed to be similar to previous trials of moderate to severe asthma, recruiting symptomatic children and younger patients, and their asthma control questionnaire (ACQ) averaged ≥1.5. However, this study also looked significantly at different sites, including a duration of 12 weeks, requiring patients with high doses of ICS and at least one additional controlled drug (LABA or LTRA). Although this study of 5 μg of tiotropium bromide (1 /day) treatment did not achieve a statistically significant improvement in FEV1 results, but also failed to further dose analysis, in the morning and evening before the peak flow rate (PEF) have some improvement, there are also some useful trends on the score.

What can pediatricians get from these two large clinical studies? First, studies of moderate to severe asthma have shown that tiotropium bromide(136310-93-5) may be clinically important bronchodilator for this age group. It must be noted, however, that this test did not yield a more favorable conclusion about tiotropium than LABA. In fact, in moderate to severe asthma trials, 30% of children must stop LABA treatment before or during the trial, and this treatment change is not common in clinical management. The effect of tiotropium is not significant in more severe childhood asthma patients, and it is important to note that studies based on adult asthma alone can not be applied directly to childhood asthma.

Why the role of tiotropium bromide(136310-93-5) in bronchodilators in children with severe asthma has not been demonstrated, and the mechanism is unclear. Perhaps this is related to the presence of different phenotypes in severe and moderate childhood asthma. In addition, since all children in severe asthma trials continue to use their controlled medications, this may suggest that supplementation with tiotropium on the basis of ICS + LABA does not provide additional benefit. Thus, the status of tiotropium in children's asthma remains to be further clarified before more clinical studies are conducted.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved